Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$253.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Aventis Pharma Ltd Recommends Final Dividend
Aventis Pharma Ltd announced that the Board of Directors of the Company at its meeting held on February 23, 2012 have recommended Final Dividend of INR29 per Equity share of INR10 for the year ended December 31, 2011.
Latest Developments for Sanofi India Ltd
- Aventis Pharma Limited Announces Acquisition Of Nutraceutical Business Of Universal Medicare Private Limited
- Aventis Pharma Limited To Acquire Universal Medicare's Nutraceutical Business In India
- Aventis Pharma Limited To Buy OTC Biz Of India's Universal Medicare For $109 Million-Reuters
- Aventis Pharma Limited Recommends Final Dividend And Special One-time Dividend
Latest Key Developments in Pharmaceuticals - Generic / Specialty
- Latvijas Zoovetapgade AS Announces Additional Reason for Trading under Surveillance-NASDAQ OMX Riga
- Ind Swift Laboratories Ltd Does Not Recommend Final Dividend
- Chang An Information Industry (Group) Co., Ltd. Announces Change of General Manager and Chairman
- Perrigo Co Announces FDA Final Approval Of Tris Pharma's Dextromethorphan Polistirex Extended-Release Oral Suspension
- Share this
- Link this
- Digg this
Follow Reuters